Novartis stock surged after its oral multiple sclerosis pill passed two late-stage trials Sep 02, 2026 · Cris Tolomia The oral drug remibrutinib cut relapse rates in patients with relapsing multiple sclerosis, beating a rival treatment in both studies Read more »
![Prediction: This Pipeline Stock's Payout Will Grow Faster Than Chevron's [or Exxon's] Over the Next 5 Years](https://media.zenfs.com/en/motleyfool.com/ce9f8ee3e848bda8f77a44da7292e1e4.jpg)
